{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:50:14Z","timestamp":1762530614578,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.adro.2022.100978","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:35:09Z","timestamp":1650861309000},"page":"100978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases"],"prefix":"10.1016","volume":"7","author":[{"given":"Tugce","family":"Kutuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuta Z.","family":"Mustafayev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorkem","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Ugurluer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Banu","family":"Atalar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muni","family":"Rubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Mittauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessika A.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McCulloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah S.","family":"Kalman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tino","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alonso N.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacklyn","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enis","family":"Ozyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.100978_bib0001","doi-asserted-by":"crossref","first-page":"94","DOI":"10.21037\/atm.2018.01.19","article-title":"Surgical approach in the oligometastatic patient","volume":"6","author":"Divisi","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.adro.2022.100978_bib0002","doi-asserted-by":"crossref","first-page":"S969","DOI":"10.21037\/jtd.2019.04.09","article-title":"Evidence for surgical resections in oligometastatic lung cancer","volume":"11","author":"Fernandez","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.adro.2022.100978_bib0003","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.14694\/EdBook_AM.2015.35.e8","article-title":"Surgery or ablative radiotherapy for breast cancer oligometastases","author":"Salama","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.adro.2022.100978_bib0004","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.adro.2022.100978_bib0005","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0006","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The oriole phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0007","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fonc.2019.00543","article-title":"A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic cancers: Where will the evidence lead?","volume":"9","author":"Al-Shafa","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0008","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0009","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/jamaoncol.2021.0687","article-title":"Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: Findings from the NRG-BR001 phase 1 trial","volume":"7","author":"Chmura","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The Hilus-Trial-A prospective Nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0011","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population based phase II trial of stereotactic ablative radiotherapy (sabr) for up to 5 oligometastases: Preliminary results of the SABR-5 trial 2021","volume":"18","author":"Olson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.adro.2022.100978_bib0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejca.2019.07.021","article-title":"The transformation of radiation oncology using real-time magnetic resonance guidance: A review","volume":"122","author":"Hall","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2022.100978_bib0013","first-page":"e2422","article-title":"A new era of image guidance with magnetic resonance-guided radiation therapy for abdominal and thoracic malignancies","volume":"10","author":"Mittauer","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.adro.2022.100978_bib0014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-guided online adaptive radiation therapy (smart) for ultracentral thorax malignancies: Results of a phase 1 trial","volume":"4","author":"Henke","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0016","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0017","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.meddos.2021.02.008","article-title":"Daily online adaptive magnetic resonance image (MRI) guided stereotactic body radiation therapy for primary renal cell cancer","volume":"46","author":"Kutuk","year":"2021","journal-title":"Med Dosim"},{"key":"10.1016\/j.adro.2022.100978_bib0018","first-page":"71","article-title":"The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey","volume":"29","author":"Seravalli","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3857\/roj.2020.00976","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: Initial clinical experience","volume":"39","author":"Ugurluer","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.adro.2022.100978_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/1748-717X-8-275","article-title":"The research registry: Patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy","volume":"8","author":"Davis","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0021","unstructured":"Common terminology criteria for adverse events (CTCAE) v4.0. Available at: https:\/\/ctep.Cancer.Gov\/protocoldevelopment\/electronic_applications\/ctc.Htm#ctc_40. Accessed January 31, 2022."},{"key":"10.1016\/j.adro.2022.100978_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.adro.2022.100978_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic body radiation therapy of adrenal metastases: A pooled meta-analysis and systematic review of 39 studies with 1006 patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100978_bib0024","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2021.11.024","article-title":"CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy","volume":"166","author":"Rodriguez","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0026","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2021.08.033","article-title":"Phase I trial of stereotactic MRI-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic ovarian cancer","volume":"112","author":"Henke","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100978_bib0027","article-title":"Stereotactic body radiotherapy for lymph node oligometastases: Real-world evidence from 90 consecutive patients","volume":"10","author":"Burkon","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0028","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.rpor.2014.10.004","article-title":"Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?","volume":"20","author":"Jereczek-Fossa","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.adro.2022.100978_bib0029","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818803597","article-title":"Stereotactic radiotherapy for oligometastases in lymph nodes-a review","volume":"17","author":"Matsushita","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.adro.2022.100978_bib0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: Techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0031","doi-asserted-by":"crossref","unstructured":"van Dams R, Wu TC, Kishan AU, et\u00a0al. Ablative radiotherapy for liver tumors using stereotactic mri-guidance: A prospective phase I trial [e-pub ahead of print]. Radiother Oncol. doi:10.1016\/j.radonc.2021.06.005, accessed January 31, 2022.","DOI":"10.1016\/j.radonc.2021.06.005"},{"key":"10.1016\/j.adro.2022.100978_bib0032","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijrobp.2020.02.025","article-title":"Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors","volume":"107","author":"Finazzi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100978_bib0033","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4149\/neo_2018_180522N333","article-title":"Recurrent oligometastatic transitional cell bladder carcinoma: Is there room for radiotherapy?","volume":"66","author":"Augugliaro","year":"2019","journal-title":"Neoplasma"},{"key":"10.1016\/j.adro.2022.100978_bib0034","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2020.06.029","article-title":"Assessing the role of stereotactic body radiation therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?","volume":"150","author":"Franzese","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2022.100978_bib0036","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100978_bib0037","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1002\/cam4.4139","article-title":"Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis","volume":"10","author":"Yoon","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.adro.2022.100978_bib0038","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ijrobp.2021.07.003","article-title":"Patterns of care, tolerability, and safety of the first cohort of patients treated on a novel high-field MR-linac within the momentum study: Initial results from a prospective multi-institutional registry","volume":"111","author":"de Mol van Otterloo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000859?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000859?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:44:07Z","timestamp":1762530247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422000859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2452109422000859"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.100978","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-Institutional Outcomes of Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy With a Median Biologically Effective Dose of 100 Gy10 for Non-bone Oligometastases","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.100978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100978"}}